AviadoBio

Another Astellas Gene Therapy Deal, This Time $50M for Option on AviadoBio Dementia Program

Astellas secured an exclusive option to license global rights to an AviadoBio gene therapy in development as a one-time treatment for a certain type of frontotemporal dementia. A Phase 1/2 test of the AviadoBio gene therapy is ongoing.

By Frank Vinluan

BioPharma, Pharma

Biotech startup AviadoBio emerges with $80M for neuro disorder gene therapies

AviadoBio’s gene therapies are designed to achieve widespread distribution throughout the central nervous system. The company’s lead program on track to begin human testing as a treatment for frontotemporal dementia.

By Frank Vinluan